Key Points
- Director Alex Hamilton sold 125,000 shares on Nov. 19 at an average price of $1.22 for $152,500, leaving him with 3,334 shares — a 97.40% reduction in his position.
- Mangoceuticals shares opened at $1.07 and were down 2.7%; the company has a market cap of $14.88M, reported ($0.69) EPS last quarter with revenue of $0.08M and extremely negative margins and ROE.
- Institutional ownership is 56.72% (Geode raised its stake by 35.4%), and analysts have an average rating of "Sell", with recent downgrades from Weiss Ratings and Wall Street Zen.
Mangoceuticals, Inc. (NASDAQ:MGRX - Get Free Report) Director Alex Hamilton sold 125,000 shares of the company's stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $1.22, for a total transaction of $152,500.00. Following the completion of the sale, the director owned 3,334 shares in the company, valued at $4,067.48. This represents a 97.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Mangoceuticals Stock Down 2.7%
MGRX opened at $1.07 on Thursday. Mangoceuticals, Inc. has a twelve month low of $0.98 and a twelve month high of $6.15. The company's 50-day moving average price is $2.02 and its two-hundred day moving average price is $1.90. The stock has a market cap of $14.88 million, a price-to-earnings ratio of -0.30 and a beta of 2.39.
Mangoceuticals (NASDAQ:MGRX - Get Free Report) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.69) EPS for the quarter. Mangoceuticals had a negative net margin of 4,253.43% and a negative return on equity of 114.63%. The firm had revenue of $0.08 million during the quarter.
Institutional Trading of Mangoceuticals
An institutional investor recently raised its position in Mangoceuticals stock. Geode Capital Management LLC grew its stake in shares of Mangoceuticals, Inc. (NASDAQ:MGRX - Free Report) by 35.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,498 shares of the company's stock after buying an additional 6,928 shares during the quarter. Geode Capital Management LLC owned 0.51% of Mangoceuticals worth $40,000 at the end of the most recent quarter. Institutional investors own 56.72% of the company's stock.
Wall Street Analyst Weigh In
MGRX has been the subject of a number of analyst reports. Weiss Ratings restated a "sell (e+)" rating on shares of Mangoceuticals in a research report on Monday. Wall Street Zen cut shares of Mangoceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, November 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of "Sell".
Check Out Our Latest Analysis on Mangoceuticals
Mangoceuticals Company Profile
(
Get Free Report)
Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
